Skip to main content
logo
Scribe Therapeutics Inc. (SCTX)
NASDAQ: SCTX · Real-Time Price · USD
20.40
+2.04 (11.11%)
At close: Jul 30, 2026, 4:00 PM EDT
21.82
+1.42 (6.96%)
Pre-market: Jul 31, 2026, 7:21 AM EDT

Scribe Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Mar '26 Dec '25 Dec '24
Net Income
-35.73-21.81-47.79
Depreciation & Amortization
2.993.082.89
Other Amortization
-03.58-
Loss (Gain) From Sale of Assets
0.010.010.12
Loss (Gain) From Sale of Investments
0.880.830.63
Stock-Based Compensation
5.444.142.85
Other Operating Activities
7.311.351.28
Change in Accounts Receivable
6.32-3.98-1.47
Change in Accounts Payable
-1.31.55-1.92
Change in Unearned Revenue
-22.79-31.4-6.78
Change in Other Net Operating Assets
-2.29-2.574.94
Operating Cash Flow
-39.15-45.21-45.24
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Mar '26 Dec '25 Dec '24
Capital Expenditures
-0.8-1.27-1.35
Investment in Securities
40.746.5414.36
Investing Cash Flow
39.945.2713.01

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Mar '26 Dec '25 Dec '24
Issuance of Common Stock
0.240.140.47
Other Financing Activities
-0.5--0.69
Financing Cash Flow
-0.270.14-0.22

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Mar '26 Dec '25 Dec '24
Net Cash Flow
0.480.19-32.44

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Mar '26 Dec '25 Dec '24
Free Cash Flow
-39.94-46.48-46.58
Free Cash Flow Growth
---
Free Cash Flow Margin
-110.09%-90.83%-169.93%
Free Cash Flow Per Share
-16.37-19.14-19.44
Levered Free Cash Flow
--13.5-
Unlevered Free Cash Flow
--12-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Mar '26 Dec '25 Dec '24
Cash Income Tax Paid
0.210.211.98
Change in Working Capital
-20.05-36.39-5.22
SEC Filings: 10-K · 10-Q